In this way, Shen et al. have recently demonstrated that c-MYC would be involved in the response to c-MET inhibitor therapy both in c-MET addicted cancer cell-lines and in derived resistance, including colorectal cell lines [11]. This evidence concerns the gene MYC and cancer.